Proprietary Blends Hide Exact Ingredient Doses Behind a Single Label Total

The Single Number That Obscures a Dozen Ingredients

Walk down the aisle of any modern wellness retailer or browse an online sports nutrition catalog, and you will encounter supplement containers bearing bold, assertive promises. Front labels routinely announce proprietary formulations engineered for cognitive focus, cardiovascular stamina, metabolic activation, or deep nocturnal recovery. Turn the bottle around to examine the Supplement Facts panel, however, and the apparent precision of those claims frequently dissolves into a single, opaque line item. Instead of an itemized list stating the exact milligram quantities of each active substance, the panel displays a collective title such as "Endurance Complex," "Neuro-Focus Matrix," or "Botanical Vitality Blend," paired with a single aggregate weight like 750 milligrams. Beneath that overarching figure sits a comma-separated roster of eight, twelve, or sometimes twenty distinct herbs, amino acids, and plant extracts, without a single individual weight attached to any of them.

This common labeling architecture is known across the nutrition industry as a proprietary blend. For the consumer standing in the aisle, it creates a psychological impression of abundance, sophistication, and synergistic formulation. The human brain naturally assumes that if a bottle lists twenty celebrated botanicals, each one must be contributing meaningfully to the physiological outcome promised on the carton. In biological reality, however, human pharmacology and nutritional biochemistry operate on strict threshold kinetics. Molecules do not produce clinical effects simply because their botanical names appear in print. An active compound must reach a specific concentration in the bloodstream and tissues to interact effectively with cellular receptors, metabolic enzymes, or transport proteins.

When a supplement manufacturer bundles multiple bioactives under a single total milligram weight, the consumer loses the ability to determine whether any single ingredient is present in an amount sufficient to exert a biological effect. A 600-milligram blend containing ten ingredients might deliver 590 milligrams of an inexpensive bulk carrier and one milligram of nine expensive, clinically validated botanicals. Because the aggregate number remains 600 milligrams, the label remains legally compliant, yet the physiological value of the product is radically compromised. Understanding why proprietary blends exist, how regulatory frameworks permit them, and how to decode the subtle clues hidden within ingredient panels is an essential skill for anyone investing in dietary supplementation.

The Regulatory Architecture of Section 101.36

To understand how proprietary blends became so prevalent on commercial shelves, one must examine the legal and regulatory framework governing dietary supplements in the United States, which serves as the de facto manufacturing standard for a substantial portion of the global supplement market. In 1994, the United States Congress enacted the Dietary Supplement Health and Education Act, widely known as DSHEA. Under DSHEA, dietary supplements were categorized as a specialized subset of foods rather than pharmaceutical drugs. This classification established distinct rules for product manufacturing, safety evaluation, and label disclosure.

The specific operational requirements for dietary supplement panels are codified under Title 21 of the United States Code of Federal Regulations, specifically Section 101.36, titled "Nutrition labeling of dietary supplements." Within this regulation, a fundamental distinction is drawn between two primary classes of dietary ingredients:

• First, dietary ingredients with established daily intake recommendations: Referred to in regulatory terminology as (b)(2) dietary ingredients, these encompass essential vitamins and minerals that possess an established Reference Daily Intake (RDI) or Daily Reference Value (DRV). Under federal law, these nutrients (such as vitamin C, calcium, magnesium, zinc, and vitamin D) cannot be hidden inside an anonymous blend. Their quantitative amounts per serving and their percentage Daily Value must be declared individually and explicitly in the nutrition table.
• Second, dietary ingredients without established daily values: Referred to in regulation as (b)(3) dietary ingredients or "other dietary ingredients," these include botanical extracts, herbal powders, amino acids, enzymes, polyphenols, and animal tissues. Because public health authorities have not established formal Daily Values for substances like ashwagandha root, curcumin, rhodiola rosea, or L-theanine, federal regulations permit manufacturers to group them together under the heading of a "Proprietary Blend" or an appropriately descriptive fanciful name.

Under 21 CFR 101.36(c), when a manufacturer creates a proprietary blend, three statutory labeling rules apply. First, the total combined quantitative weight of the blend must be declared in metric units (milligrams or grams) on the same line as the blend title. Second, all dietary ingredients contained within the blend must be listed individually, indented directly beneath the blend title or presented in a continuous linear block. Third, and most importantly, the ingredients within the blend must be listed in descending order of predominance by input weight. The substance present in the greatest quantity by weight must appear first, followed sequentially by ingredients present in lesser amounts.

While the United States codified this structure under DSHEA, other international jurisdictions take varying approaches to blend transparency. In New Zealand, dietary supplements have historically been regulated under the Dietary Supplements Regulations 1985, administered jointly with food standards enforced by the Ministry for Primary Industries (MPI) and therapeutic boundaries overseen by Medsafe. Under New Zealand law, alongside the general consumer protections of the Fair Trading Act 1986, products sold to the public must not mislead consumers regarding their composition, potency, or therapeutic properties. While proprietary mixtures of botanical ingredients are marketed in New Zealand, regulatory bodies scrutinize claims where the quantity of an active ingredient is so negligible that promoting its presence constitutes misleading or deceptive conduct.

Similarly, in the United Kingdom and the European Union, food supplement directives maintain stricter requirements regarding quantitative ingredient declarations. Under European labeling principles, if the labeling or advertising of a food supplement places special emphasis on the presence of a specific botanical or bioactive compound, the manufacturer is generally required under Quantitative Ingredient Declaration (QUID) rules to state the percentage or exact weight of that emphasized ingredient. Consequently, multinational supplement companies frequently maintain distinct packaging formulations: a proprietary blend label for North American distribution, and a fully disclosed, itemized milligram panel for European and Australasian compliance.

Trade Secrets Versus Commercial Concealment

When industry trade associations and supplement brand executives defend the continued use of proprietary blends, their primary public argument centers on the protection of intellectual property and trade secrets. Formulating a truly effective, synergistic dietary supplement requires significant investment in scientific research, clinical piloting, organoleptic testing, and stability assessment. An innovative company might spend years identifying an exact ratio of three synergistic herbal extracts that optimize cognitive alertness without elevating blood pressure.

If that pioneering company were forced to publish the exact milligram quantity of each component on the back of the bottle, competitors with larger marketing budgets and existing retail distribution networks could theoretically copy the exact formula overnight. Because dietary ingredients are naturally occurring substances rather than novel synthetic molecules, they generally cannot be protected by composition-of-matter pharmaceutical patents. Proponents of proprietary blends argue that DSHEA deliberately provided the blend exemption to prevent conglomerates from copying the handcrafted recipes of small, innovative herbal formulators.

While this intellectual property justification possesses legitimate historical merit in specific niche applications, clinical researchers and regulatory analysts have increasingly questioned whether trade-secret protection remains the primary driver of proprietary blends in modern commerce. In May 2023, a landmark analytical paper co-authored by scientists from the National Institutes of Health (NIH) Office of Dietary Supplements, the Food and Drug Administration (FDA) Center for Food Safety and Applied Nutrition, and the Consumer Healthcare Products Association was published in The Journal of Nutrition. Led by Dr. Leila G. Saldanha and Dr. Johanna T. Dwyer, the research team analyzed over 155,000 commercial supplement labels cataloged within the federal Dietary Supplement Label Database (DSLD).

Their findings revealed the extraordinary scale of proprietary blends across the consumer landscape. Overall, 34 percent of all product labels in the national database grouped dietary ingredients into blends, and 21 percent explicitly utilized proprietary blends that withheld individual ingredient amounts. When the researchers examined specific market categories, the prevalence rose dramatically: proprietary blends appeared in 29 percent of multi-combination products, 23 percent of botanical-with-nutrient supplements, and 18 percent of pure botanical formulations.

Crucially, the authors pointed out a fundamental legal reality that undermines the trade-secret defense. Under United States patent and trademark law, registering a trademark for a fanciful blend name, such as "CogniDrive Matrix" or "ThermoBurn Complex," grants exclusive rights only to the commercial name, not to the underlying chemical formulation. Furthermore, modern analytical chemistry, including high-performance liquid chromatography and mass spectrometry, allows any well-funded competitor to reverse-engineer the precise chemical composition of an over-the-counter capsule in a commercial laboratory within several days. The entity kept completely in the dark by a proprietary blend is rarely the sophisticated competitor; it is almost always the individual consumer who purchases and consumes the product.

When the amount of a dietary ingredient listed within a proprietary blend is not declared, it is not possible to accurately calculate exposures and intakes of that ingredient or determine doses used in clinical trials from label information. — Dr. Leila G. Saldanha

The public health implications highlighted by Dr. Saldanha and her colleagues are profound. When individual dosages are concealed behind an aggregate number, clinical nutritionists, toxicologists, and consumer health researchers cannot calculate actual nutrient intake or evaluate whether a formulation aligns with peer-reviewed human trials.

The Economics of Fairy Dusting on Product Labels

If proprietary blends do not prevent industrial reverse-engineering, why do they remain so pervasive across commercial product lines? The answer lies in the powerful economic incentives that govern dietary supplement manufacturing and marketing. Within the contract manufacturing industry, formulators openly discuss a practice colloquially known as "fairy dusting," or sometimes referred to as "window dressing" or "label padding."

Fairy dusting refers to the deliberate commercial strategy of including an expensive, clinically researched, or trendy ingredient in a formulation at a minuscule, biologically inert dosage, simply to legally claim its presence on the product packaging. The economic mechanics driving this practice are straightforward:

• Raw material cost disparities: In the global supply chain, bulk filler substances and generic amino acids are extraordinarily cheap. Generic taurine, glycine, maltodextrin, or rice flour can cost manufacturers between five and ten dollars per kilogram. In stark contrast, patented, clinically validated botanical extracts, such as standardized ashwagandha extracts, branded citicoline, or high-potency Boswellia serrata standardized to 30 percent AKBA, frequently cost between two hundred and eight hundred dollars per kilogram.
• The cost equation of full dosing: If a brand creates a comprehensive focus supplement containing five clinically validated branded ingredients at their proven clinical doses (for example, 600 milligrams of KSM-66 ashwagandha, 250 milligrams of Cognizin citicoline, 150 milligrams of Alpha-GPC, 100 milligrams of standardized Rhodiola, and 200 milligrams of L-theanine), the raw material cost per bottle might exceed twenty-five to thirty dollars before packaging, shipping, and retail markups.
• The financial temptation of the blend: By creating a 1,000-milligram "Cognitive Performance Proprietary Blend," the manufacturer can formulate the product with 950 milligrams of inexpensive taurine or generic choline bitartrate, and add a single milligram of each of the five premium botanicals. The raw material cost instantly plummets to two dollars per bottle. Yet, on the front panel and in marketing copy, the brand can legally display photographs of the exotic herbs, cite clinical trials conducted on those botanicals, and tell consumers that their formula contains the exact ingredients celebrated by modern neuroscience.

The clinical consequences of fairy dusting were thoroughly evaluated in a 2018 review published in the Journal of the International Society of Sports Nutrition by Dr. Patrick S. Harty and colleagues. Investigating multi-ingredient pre-workout supplements (MIPS), the researchers found that products utilizing proprietary blends routinely underdosed key ergogenic compounds. While ingredients like beta-alanine and L-citrulline possess well-documented physiological thresholds required to buffer muscular acidosis or enhance nitric oxide synthesis, proprietary pre-workout blends frequently contained aggregate weights smaller than the clinical threshold of a single constituent ingredient. A consumer purchasing a pre-workout with a 4,000-milligram proprietary blend containing L-citrulline, beta-alanine, creatine, and tyrosine might feel an energetic surge due to high doses of cheap caffeine anhydrous, while the underlying ergogenic amino acids exist at levels incapable of improving cellular endurance or athletic adaptation.

The Mathematical Ceiling Revealed by Descending Weight Order

While proprietary blends conceal exact milligram numbers, they cannot escape basic arithmetic. Federal regulations in 21 CFR 101.36(c)(2) mandate that every ingredient within a proprietary blend must appear in strict descending order of predominance by weight. This single regulatory requirement provides consumers with a powerful analytical tool. By applying simple mathematical deduction to the total blend weight and the position of each ingredient in the list, an astute reader can calculate the absolute maximum mathematical ceiling for any subordinate ingredient.

Consider a practical, real-world scenario commonly found on retail shelves: an evening relaxation supplement promoting a "Deep Rest Botanical Blend" with a declared total weight of 600 milligrams. The label lists six ingredients in the following descending sequence:

1. L-Theanine
2. Chamomile Flower Powder
3. Lemon Balm Extract
4. Passionflower Extract
5. Magnolia Bark Extract
6. Ashwagandha Root Extract

At first glance, a wellness consumer might feel reassured seeing ashwagandha, magnolia bark, and L-theanine all present in the same capsule. But let us apply the rule of descending weight order to calculate what is mathematically possible within that 600-milligram envelope.

Because the ingredients must descend by weight, the first ingredient (L-Theanine) must represent the largest single portion of the blend. In human clinical trials, L-theanine is typically administered at a dose of 200 milligrams to promote alpha-wave relaxation. If the manufacturer included an honest 200 milligrams of L-theanine, that leaves exactly 400 milligrams of total weight remaining to be divided among the subsequent five ingredients.

Now, examine the second ingredient: Chamomile Flower Powder. To comply with descending order, chamomile cannot exceed the weight of the preceding ingredient (200 milligrams). If chamomile is present at 150 milligrams, the remaining weight for the final four ingredients drops to 250 milligrams. Moving to the third ingredient, Lemon Balm Extract, its weight must be lower than chamomile. If lemon balm is present at 100 milligrams, only 150 milligrams remain for Passionflower, Magnolia Bark, and Ashwagandha combined.

Now, consider the position of Ashwagandha Root Extract, which sits in the sixth and final position on the list. Because every preceding ingredient must be equal to or heavier than the ingredients following it, the mathematical maximum that the final ingredient could possibly contain is derived by dividing the remaining weight across the final positions. Under the most optimistic formulation scenario imaginable, where all remaining ingredients are almost equal:

• Passionflower Extract: 52 milligrams
• Magnolia Bark Extract: 50 milligrams
• Ashwagandha Root Extract: 48 milligrams

In peer-reviewed clinical literature, standardized ashwagandha root extract demonstrates therapeutic efficacy for stress resilience and cortisol modulation at doses between 300 and 600 milligrams daily. In this commercial bottle, however, the absolute physical maximum of ashwagandha that could mathematically fit inside the capsule is 48 milligrams, less than one-tenth of its clinically studied threshold. In reality, commercial formulations rarely distribute weight evenly among final ingredients; the first two components often make up 85 to 90 percent of the total blend mass, leaving the final three or four botanicals with trace quantities of two to five milligrams each.

Whenever you encounter a multi-ingredient proprietary blend, look at the total weight, count the number of ingredients, and look at the position of the specific herb you are seeking. If a product boasts twenty ingredients inside a 500-milligram blend, the mathematical average per ingredient is a mere 25 milligrams. If the botanical you care about sits in the lower half of that list, its presence is almost certainly sub-therapeutic fairy dusting.

Safety Risks and the Difficulty of Managing Interactions

While the economic waste of paying premium prices for underdosed botanicals is frustrating, proprietary blends present far more serious concerns when viewed through the lens of physiological safety, adverse event reporting, and pharmaceutical drug interactions. Supplements are biologically active substances that alter human physiology. When a label conceals exact milligram quantities, managing personal health risks becomes exceptionally difficult.

The first safety hazard involves hidden stimulant loads. In energy formulations, thermogenic weight-loss products, and pre-workout powders, manufacturers frequently include multiple distinct botanical sources of central nervous system stimulants. A proprietary "Metabolic Fire Complex" might contain caffeine anhydrous, guarana seed extract, green tea extract, yerba mate, and kola nut. While federal regulations require caffeine added in its pure synthetic anhydrous form to be declared, caffeine naturally occurring within whole botanical extracts can be grouped inside a proprietary blend without itemizing the exact milligram yield of the methylxanthines.

For an individual with mild hypertension, cardiac arrhythmias, generalized anxiety, or gastrointestinal sensitivity to stimulants, consuming a product with an unquantified stimulant matrix is hazardous. A blend labeled as 800 milligrams might deliver 150 milligrams of caffeine or 450 milligrams of caffeine, depending on the concentration and standardization of the botanical extracts. Without an exact milligram disclosure, the consumer cannot track their total daily stimulant exposure or anticipate physiological side effects such as tachycardia, jitteriness, sleep architecture disruption, or acute spikes in systolic blood pressure.

A second critical safety dimension involves pharmacokinetic interactions with prescription medications. Many botanical bioactives exert potent inhibitory or inductive effects on the cytochrome P450 enzyme superfamily in the liver, as well as drug efflux pumps like P-glycoprotein in the intestinal epithelium:

• St. John's Wort (Hypericum perforatum): A well-documented inducer of the CYP3A4 enzyme and P-glycoprotein, capable of accelerating the clearance of oral contraceptives, immunosuppressants, anticoagulants, and antiretroviral therapies.
• Ginkgo Biloba: Contains ginkgolides that inhibit platelet-activating factor, potentially augmenting the risk of spontaneous bleeding when combined with antiplatelet drugs like aspirin or anticoagulant medications like warfarin.
• Berberine: An alkaloid that inhibits CYP3A4, CYP2D6, and CYP2C9, dramatically altering the circulating plasma concentrations of statins, blood pressure medications, and metformin.
• Milk Thistle (Silybum marianum): Standardized silymarin extracts can modulate glucuronidation pathways and hepatic transporter kinetics.

When a patient visits their primary care physician or clinical pharmacist for a medication review, they are advised to bring a list of all dietary supplements they consume. If a patient presents a bottle containing a proprietary blend that lists Ginkgo Biloba, St. John's Wort, or Piperine (black pepper extract) without dosages, the clinician cannot perform a risk-benefit assessment. There is no way for a doctor to know whether the St. John's Wort is present at a negligible five-milligram tracer level or a potent 300-milligram standardized therapeutic level that will clear their prescription medication from the body.

Furthermore, when an adverse reaction does occur, toxicologists and public health agencies are severely hampered. When an individual presents to an emergency department with acute hepatic distress or sudden hypertension after taking a multi-ingredient supplement, medical professionals must analyze the product label to identify the causative agent. If the label displays only an aggregate proprietary matrix, identifying which botanical or alkaloid triggered the toxicity becomes an exercise in diagnostic guesswork.

What Full Label Disclosure Looks Like on Modern Shelves

In response to consumer frustration, regulatory scrutiny, and a growing demand for scientific rigor, an increasing segment of the dietary supplement industry is deliberately abandoning proprietary blends. A distinct philosophical shift toward 100 percent transparent labeling, often described as "fully disclosed" or "non-proprietary" formulations, is reshaping modern product design.

A truly transparent supplement label treats the consumer as an informed, capable partner in their own health decisions. When evaluating a quality product on today's market, transparent formulations display several distinct characteristics:

• Complete milligram disclosure: Every single active ingredient inside the capsule, tablet, or scoop is printed with its individual, precise weight in milligrams, micrograms, or grams. There are no sub-grouped matrices, no aggregate totals, and no hidden quantities.
• Explicit botanical specification: Quality botanical formulations identify the precise genus and species of the plant in Latin binomial nomenclature (for example, Withania somnifera rather than simply "ashwagandha").
• Plant part declaration: The label explicitly names the anatomical part of the plant utilized in the extraction, such as root, aerial parts, leaf, seed, or fruit body. The chemical profile of a botanical often varies dramatically depending on the plant part; the root of a plant may contain beneficial adaptogenic compounds while the leaves contain inactive or irritating tannins.
• Standardized bioactive percentages: High-quality manufacturers disclose the exact percentage of active marker compounds achieved through standardization. Rather than stating "Turmeric Root Extract 500 mg," a transparent label specifies "Turmeric Root Extract (Curcuma longa), 500 mg, standardized to 95% total curcuminoids (475 mg)." This informs the buyer of the exact biological potency delivering the intended cellular effect.
• Third-party quality verification: Transparent brands routinely invest in voluntary third-party testing and certification programs through independent auditing organizations such as NSF International, the United States Pharmacopeia (USP), Informed Sport, or the Banned Substances Control Group (BSCG). These independent seals confirm that what is stated on the label matches what is inside the bottle, and that the product is free from heavy metals, microbial pathogens, and unlisted pharmaceutical adulterants.

Brands that transition to full disclosure demonstrate that efficacy and consumer trust are more valuable than the short-term profit margins gained through fairy dusting. When a company formulates a product with genuine, clinically validated doses, it has every commercial incentive to display those numbers prominently. Hiding doses behind a proprietary blend is almost always an admission that the numbers cannot withstand clinical comparison.

A Practical Audit Checklist Before Purchasing Any Blend

Navigating supplement aisles requires an objective, structured approach. When considering a product that contains a proprietary blend or complex multi-ingredient formula, you can apply a simple five-step evaluation checklist to protect your wallet and your health:

• Step 1: Calculate the average ingredient weight: Look at the declared total weight of the proprietary blend in milligrams, and count the number of individual ingredients listed beneath it. Divide the total weight by the number of ingredients. If the blend declares 400 milligrams and lists twelve ingredients, the average weight is 33 milligrams per ingredient. Ask yourself: Can the bioactives you are seeking produce clinical benefits at an average dose of 33 milligrams? If the clinical dose for an ingredient is 500 milligrams, it cannot possibly fit inside that bottle.
• Step 2: Check the position of key marketing ingredients: Review the descending order of ingredients. Identify where the primary botanical advertised on the front of the box sits in the sequence. If the product is marketed as a "Lion's Mane Nootropic Booster," but Lion's Mane mushroom extract sits in seventh position behind caffeine, taurine, and tyrosine, its contribution to the formula is likely marginal.
• Step 3: Match the formula against peer-reviewed clinical trials: Before purchasing a supplement for a specific wellness goal, take five minutes to search reputable scientific databases such as PubMed, the Cochrane Library, or examine.com. Identify the exact therapeutic dosage range established in human randomized controlled trials for the active compound. Compare that validated range against the total blend weight. If a clinically proven botanical requires 600 milligrams daily, and the entire proprietary blend totals only 350 milligrams, the product cannot deliver the studied outcome.
• Step 4: Scrutinize the presence of hidden stimulants: If the formula is designed for energy, focus, or fat loss, examine the blend for multiple botanical sources of caffeine, synephrine, or yohimbine (such as guarana, bitter orange extract, green tea extract, and green coffee bean). If the individual yields of these stimulants are not explicitly stated, assume the product may deliver an unpredictable stimulant load.
• Step 5: Consult your healthcare professional with the exact panel: If you are pregnant, nursing, under the age of eighteen, managing an existing medical condition, or taking prescription pharmaceuticals, take the complete packaging panel to your general practitioner, registered dietitian, or pharmacist before consuming the product. Healthcare providers need to assess real milligram quantities to safeguard against contraindications and hepatic drug interactions.

Dietary supplements are designed to support and complement healthy nutritional habits, not to replace a balanced diet, restorative sleep, or evidence-based medical treatment. Supplements are not pharmaceutical medicines and cannot diagnose, cure, mitigate, prevent, or treat any clinical disease. When you choose to include a supplement in your daily routine, you deserve complete transparency regarding every milligram entering your body. By rejecting opaque proprietary blends and demanding fully disclosed, third-party verified formulations, consumers drive the entire wellness industry toward greater accountability, clinical validity, and safety.

Sources: The Journal of Nutrition (PMC10196566); Journal of the International Society of Sports Nutrition (PMC6083582); United States Code of Federal Regulations, 21 CFR 101.36; New Zealand Legislation, Fair Trading Act 1986; New Zealand Legislation, Dietary Supplements Regulations 1985; United States Food and Drug Administration Dietary Supplement Labeling Guide.

Sources

pmc.ncbi.nlm.nih.gov

www.ecfr.gov

www.fda.gov

pmc.ncbi.nlm.nih.gov

www.legislation.govt.nz

www.legislation.govt.nz

This article is for general education and does not replace advice from a qualified healthcare professional.